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Tau is a microtubule-associated protein that is expressed in neurons. However, in a
group of neurodegenerative diseases named tauopathies – characterized by an increase
in aggregated and/or hyperphosphorylated Tau – the protein accumulates inside other
cells, such as astrocytes and microglia. Given that these glial cells do not produce
Tau, its presence can be explained by internalization from the extracellular medium and
consequent formation of Tau aggregates. Among internalization mechanisms, heparan
sulfate proteoglycans (HSPGs) have been proposed to be responsible for fibrillary Tau
uptake in various cell types. Here we studied whether monomeric Tau, which has been
observed to be internalized by glial cells such as microglia, was also taken up by
astrocytes. Although this Tau form was internalized from the extracellular medium by
these cells, the mechanism of uptake was found to be independent of HSPGs.
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INTRODUCTION
Microtubule-associated protein Tau is expressed in neurons in the central nervous system
(CNS) (Weingarten et al., 1975; Drubin and Kirschner, 1986). The abnormal aggregation and
hyperphosphorylation of Tau accumulated within the cells is a common pathological hallmark
of a group of neurodegenerative diseases named tauopathies (Spires-Jones et al., 2009; Medina
et al., 2016). In this regard, the accumulation of this pathological and toxic Tau species in glial
cells, specifically microglia and astrocytes, is described in several tauopathies (Buee and Delacourte,
1999; Kovacs et al., 2016; Ferrer et al., 2018). Given that glial cells do not contain endogenous Tau,
the presence of this protein in this cell type can only be explained by its internalization from the
extracellular milieu. In Alzheimer’s disease (AD), the most prevalent tauopathy, and Tau propagates
following a stereotypical pattern (Braak and Braak, 1991). In the context of this disease, Tau is
secreted to the medium and this extracellular form of the protein is taken up by a range of cells,
including neurons, and glial cells (Gomez-Ramos et al., 2006; Calafate et al., 2015). Consequently,
this internalization contributes to the spread of Tau from cell to cell (Holmes and Diamond, 2014;
Hyman, 2014; Medina and Avila, 2014b).
Tau can be internalized by glial cells through several mechanisms (Leyns and Holtzman, 2017).
In this regard, Tau aggregates are taken up by cultured cells, primary neurons, and brain through
heparan sulfate proteoglycans (HSPGs) (Holmes et al., 2013; Stopschinski et al., 2018; Yamada and
Hamaguchi, 2018). Furthermore, Tau fibril species are internalized in astrocytes via the lysosomal
pathway (Martini-Stoica et al., 2018). These and other observations thus indicate that aggregated
Tau is directly related to the progression of tauopathies. However, because monomeric Tau is
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considered less pathogenic, its internalization, and role in the
progression of these diseases have received little attention. We
have previously reported that monomeric Tau is internalized
by microglia through a specific receptor, namely CX3CR1
(Bolos et al., 2017a). Furthermore, Tau triggers a pro-
inflammatory profile through p38 MAPK in these cells, thereby
contributing to the progression of neurodegeneration (Perea
et al., 2018a). However, the uptake of monomeric Tau in
astrocytes remains unknown.
To increase knowledge of Tau propagation mechanisms, and
based on previous studies highlighting the role of HSPGs in
the uptake of fibrillary Tau, here we addressed the involvement




Wistar rats were used for the astrocyte primary culture
experiments. The animals were obtained from the CBMSO
(Centro de Biología Molecular Severo Ochoa) animal facility
and were housed in a specific pathogen-free colony facility,
in accordance with European Community Guidelines (directive
86/609/EEC), and handled following European and local animal
care protocols (AEEC-CBMSO-62/14).
Primary Cultures
Astrocytes were cultured from the cerebral cortices of P0-P3 rats.
Cortices were dissected, stripped of meninges, and digested with
0.1% trypsin at 37◦C in HBSS (Gibco, United States) medium for
10 min. Trypsinization was stopped by the addition of DMEM
culture medium supplemented with 10% fetal bovine serum
(Gibco, United States), 100 U/mL of penicillin, and 0.1 mg/mL
of streptomycin (Gibco, United States). A single-cell suspension
of the digested tissue was obtained by repeated pipetting. Cells
were seeded into a 75-ml flask and cultured in medium at 37◦C
in humidified 5% CO2 – 95% air for 10 days. They were then
seeded onto 12-well plates (2 × 105 cells/well). Adherent cells
were incubated for 72 h before being used for the experiments.
For immunocytochemistry experiments, the cells were seeded
onto 24-well plates (1× 105 cells/well) with coverslips.
Human Monomeric Tau
The recombinant human Tau isoform, containing 2 N-terminal
inserts, and 4 microtubule binding repeats (Avila et al., 2016),
was isolated as previously described (Medina et al., 1995; Perea
et al., 2018a). One mg/ml of purified Tau was labeled with
sulfoindocyanine Cy5 dye (GE Healthcare, United Kingdom) as
described previously (Gomez-Ramos et al., 2009) and following
the manufacturer’s recommendations.
Tau Internalization Assay
Primary astrocyte cultures were treated with either 1 µM of Tau-
Cy5 or PBS-Cy5 for between 0 to 24 h. In the case of heparin or
heparinase experiments, cultures were pre-treated with 20 µg/ml
of heparin (Sigma, United States) or 10 mU/ml of heparinase III
(Sigma, United States) for 3 and 2 h, respectively before treatment
with Tau-Cy5 or PBS-Cy5, as described above. Afterward, the
cells were washed three times with PBS in order to remove excess
Tau attached to the membrane. They were then prepared for
immunocytochemistry or immunoblotting analysis.
Chinese Hamster Ovary (CHO) Cell Line
1.2× 105 cells/well were plated in a 24-well plate with coverslips.
After 24 h, cells were treated with heparinase at 10 and
100 mU/ml or PBS, in the case of control conditions, for 2 h.
Afterward, the cells were washed three times with PBS and
prepared for immunocytochemistry as described below.
Immunocytochemistry
After treatment, primary, culture and CHO cells were fixed in 4%
paraformaldehyde in PBS for 15 min at room temperature (RT)
and washed three times in PBS. Cells were then permeabilized
with PBS containing 0.2% Triton X-100 for 10 min at RT
and washed three times in PBS. After 30 min of blocking
with 1% bovine serum albumin (BSA) in PBS containing 0,1%
Tween20, the astrocytic cells were stained with rabbit anti-
GFAP (1:1000, Synaptic Systems, Germany), and mouse anti-
Cy5 (1:2000, Abcam, United Kingdom). CHO cells were stained
with mouse anti-HSPG 10E4 (1:100, AMSbio, United Kingdom).
All antibodies were diluted in blocking solution and incubated
overnight at 4◦C. The next day, cells were washed three times
in PBS and then incubated for 1 h at RT with a donkey anti-
rabbit IgG conjugated to Alexa Fluor 488 and donkey anti-mouse
IgG conjugated to Alexa Fluor 647 (1:1000, Thermo Fisher
Scientific, United States) for astrocytes, and donkey anti-mouse
I gG conjugated to Alexa Fluor 488 (1:1000, Thermo Fisher
Scientific, United States) for CHO cells. Finally, cells were washed
three times in PBS, nuclei were labeled with DAPI (1:5000, Merck,
Germany) for 10 min and rinsed with PBS.
Confocal Image Acquisition and Image
Analysis
Confocal stacks of images were obtained in a Zeiss LSM800
confocal microscope under 25× and 63× oil objectives. For
the 25× objective the numerical aperture was 0.8, the interval
between stacks: 670 nm and the size of the smallest pixel:
312 nm × 312 nm. In the case of 63× objective the numerical
aperture was 1.4, the interval between stacks: 300 nm and the size
of the smallest pixel: 132 nm× 132 nm. The quantification of the
images was carried out on the maximum projection images using
the 25× objective. Representative images were obtained with a
63× objective. Images were analyzed using ImageJ Version 1.50i
(National Institutes of Health, United States).
Fluorescence intensity analysis: internalized Tau-Cy5 was
measured by quantifying the levels of Cy5 staining inside cells. To
this end, the contour of individual cells was drawn in the GFAP
channel and the total area was measured. Images were subjected
to an invariant threshold and the Cy5+ area above the threshold
was measured and then divided by the selected area of the cell.
To determine the amount of HSPGs in CHO cells, images were
subjected to an invariant threshold and the HSPG+ area above
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the threshold was measured and then divided by the selected
area of the cell. Data relative to fluorescence intensity are thus
presented as % of positive area. 150 astrocytes or 50 CHO cells
were analyzed for each experimental condition and time point.
Immunoblotting
The levels of Tau and β-actin in primary astrocyte cultures
were determined by western blotting. After treatments, cells
were lysed in RIPA buffer [50 mM Tris–HCl, pH 7.4, 150 mM
NaCl, 1% Triton X-100; 0.5% Sodium Deoxycholate, 0.1%
SDS, and protease inhibitor mixture (Roche, Switzerland)].
Proteins were then separated on 10% sodium dodecyl sulfate-
polyacrylamide gels in reducing conditions before being
transferred electrophoretically onto nitrocellulose membranes
(GE healthcare, United Kingdom). Membranes were blocked
for 2 h with 5% in BSA in 50 mM of Tris–buffered saline,
pH 8, containing 0.05% of Tween 20 (TBS-Tween). They were
then incubated overnight at 4◦C with the following antibodies:
mouse anti-Tau5 antibody (1:1000, Merck, Germany); mouse
anti-Cy5 antibody (1:1000, Abcam, United Kingdom); or mouse
anti-β-actin antibody (1:1000, Sigma, United States). Protein
expression was detected using HRP-conjugated secondary
antibodies (1:2000, Agilent, United States). For quantification of
immunoreactivity, images of blots were analyzed using ImageJ
Version 1.50i (National Institutes of Health, United States). All
results were obtained in at least three independent experiments.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism software,
Version 7.0a (United States). Data were tested by two-way
analysis of variance. Post-hoc comparisons were analyzed using
Holm-Sidak’s or Tukey’s test. Differences were considered
statistically significant when the probability, p, of the null
hypothesis was ≤0.05. Data are presented as the means± SE.
RESULTS
Astrocytes Internalized Monomeric Tau
From the Extracellular Medium
The internalization of Tau fibrils into astrocytes has been
described (Martini-Stoica et al., 2018). However, the uptake
of monomeric Tau, which has a key role in tauopathies (Fox
et al., 2011; Gerson et al., 2014; Bolos et al., 2017b), by these
cells remains unknown. In this regard, here we studied the
internalization of human monomeric Tau (Tau) in astrocyte
primary cultures at time points ranging from 0 to 24 h
(Figure 1). To facilitate the detection of Tau inside the cells by
immunocytochemistry, the protein was labeled with Cy5 (Tau-
Cy5), as previously described (Bolos et al., 2015). PBS-Cy5 was
used as a control. The amount of Cy5 (in red) internalized (GFAP,
green color) was measured at different times (Figures 1A–G).
At time 0 h, no Cy5 was detected inside the cells (Figure 1A).
However, as early as 30 min, Cy5 staining, denoting Tau presence,
was observed and increased over time until 24 h, when seems to
reach a plateau (Figures 1B–G).
To corroborate that the Tau detected in the astrocytes derived
from the extracellular medium rather the cells themselves, the
cells were treated with Tau-Cy5, or control (PBS-Cy5). The
amount of Tau internalized was then analyzed in cell lysates
by western blot using Tau5, a Tau antibody (Figure 1H). The
quantification is shown in Figure 1F. The presence of Tau protein
was not detected at early times, thereby supporting the notion
that the source of Tau is extracellular (Figure 1H). However, after
1 h and until 24 h, Tau increased inside the cells compared to
controls (Figures 1H,I).
These results confirm that Tau in astrocytes derives
from the extracellular medium and that its internalization
increases over time.
Heparan Sulfate Proteoglycans (HSPGs)
Are Not Involved in the Internalization of
Monomeric Tau
The internalization of Tau in aggregate and fibrillary forms
through HSPGs has been studied using various cell models
(Holmes et al., 2013; Martini-Stoica et al., 2018). However,
the implication of these structures in the internalization of
monomeric Tau has been addressed only in neurons (Katsinelos
et al., 2018; Rauch et al., 2018). Hence, following the same
protocol described in previous studies (Ihse et al., 2017), here
we studied the uptake of monomeric Tau by astrocytes through
HSPGs (Figure 2). Using primary cultures of astrocytes, the
internalization of Tau was analyzed at different times in the
presence or absence of heparin (Figures 2A,B). Heparin can be
used to competitively inhibit binding to HSPGs and prevent Tau
uptake via these structures (Holmes et al., 2013). After 1 and
3 h of heparin treatment, Tau protein was detected inside the
cells independently of the presence of heparin (Figures 2A,B).
In addition, the amount of Tau in primary cultures treated
with heparinase, which removes HSPGs (Figures 2C,D), was
measured. After 1 h, Tau was found inside the astrocytes that were
treated with heparinase, in the same way as those not treated.
These results were confirmed using immunocytochemistry
approach (Figures 2E,F). The quantification (Figure 2E) and
the representative images after 1 h of Tau-Cy5 treatment with
or without heparin and heparinase (Figure 2F), confirm that
the amount of Tau inside the cells were the same. In order to
be sure that HSPGs were removed properly, CHO cells were
treated with 0 (control), 10, or 100 mU/ml of heparinase for
2 h (Figures 2G,H). The representative images (Figure 2G) and
quantification (Figure 2H) confirm that the amount of HSPGs
was reduced after heparinase treatment. As a control, the total
area of the cells was measured after the heparinase treatment and
no changes were observed (Figure 2I). These results therefore
suggest that monomeric Tau is internalized by these cells through
a mechanism that is not mediated by HSPGs.
DISCUSSION
Tauopathies are a group of disorders characterized by the
abnormal accumulation of the microtubule-associated protein
Tau (Goedert and Spillantini, 2011). In tauopathies such as AD,
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FIGURE 1 | Astrocytes internalized extracellular Tau in vitro. Astrocytes derived from primary cultures were incubated with Tau-Cy5 at different time points (A–G).
(A–F) show representative immunofluorescence images of cells stained for GFAP (green) and Tau (red). Representative images of times 0 h (A), 30 min (B), 1 h (C),
3 h (D), 6 h (E), and 24 h (F) are shown. (G) shows quantification of results from immunofluorescence analysis showing % Cy5/GFAP fluorescence intensity present
in cells treated with Tau-Cy5 relative to the control PBS-Cy5. (H) western blot and (I) quantification, of Tau in cell lysates from 0 to 24 h. Means and SE, PBS
0 h = 0.03 ± 0.006; Tau 0 h = 0.05 ± 0.01; PBS 1 h = 0.02 ± 0.002; Tau 1 h = 0.14 ± 0.03; PBS 3 h = 0.01 ± 0.002; Tau 3 h = 0.09 ± 0.03; PBS
6 h = 0.01 ± 0.003; Tau 6 h = 0.11 ± 0.04; PBS 24 h = 0.01 ± 0.002; and Tau 24 h = 0.12 ± 0.03. An N = 5 independent experiments were performed. Bars show
means ± SE. ∗p ≤ 0.05, ∗∗p ≤ 0.01, and ∗∗∗p ≤ 0.001. Scale bar, 50 µm.
intracellular Tau forms filamentous of hyperphosphorylated and
aggregated protein inside the cells that is associated with the
progression of neurodegeneration (Ballatore et al., 2007; Goedert
and Spillantini, 2011; Arendt et al., 2016; Medina et al., 2016).
In these diseases, Tau inclusions have also been reported in
glial cells, such as microglia (Odawara et al., 1995; Bolos et al.,
2015; Leyns and Holtzman, 2017) and astrocytes (Kovacs et al.,
2016; Ferrer et al., 2018), despite their lack of Tau expression.
These observations could be explained by the internalization
of Tau previously released into the extracellular space through
physiological and pathological mechanisms (Simon et al., 2012;
Pooler et al., 2013; Perez et al., 2016) and its posterior secretion
again by neighboring cells (Perea et al., 2018b). The transfer of
Tau between brain cell populations (Holmes and Diamond, 2014;
Medina and Avila, 2014a; Calafate et al., 2015; Maphis et al., 2015)
leads to its propagation throughout the CNS.
Although fibrillary and aggregated Tau, which are formed
by hyperphosphorylated Tau, are considered a histopathological
hallmark of tauopathies (Selkoe et al., 1982), monomeric forms
of the protein are also involved in toxicity and the spread of
the disease (Gomez-Ramos et al., 2006; Cowan and Mudher,
2013; Gerson et al., 2014; Bolos et al., 2017b; Perea et al., 2018a).
In this regard, we previously reported the internalization of
extracellular monomeric Tau by microglia (Bolos et al., 2015), and
in the present work we confirmed the same event in astrocyte
primary cultures. These results support the notion that glial
cells contribute to the cell-to-cell propagation of Tau (Leyns and
Holtzman, 2017; Perea et al., 2018b).
Several mechanisms of extracellular Tau internalization in
neurons (Wang et al., 2017; Katsinelos et al., 2018) and glial
cells have been described (Luo et al., 2015; Bolos et al., 2017a).
Among them, HSPGs have been shown to be involved in the
uptake of fibrillary and aggregated Tau (Holmes et al., 2013;
Martini-Stoica et al., 2018; Rauch et al., 2018). However, here
we have demonstrated that the uptake of monomeric Tau in
astrocytes is independent of HSPGs. Both in the presence of
heparin, which competes with Tau for binding to HSPGs, as
well as after HSPGs removal using heparinase, the amount of
internalized Tau in astrocytes was the same. This observation
implies that another internalization mechanism is responsible for
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FIGURE 2 | Internalization of monomeric Tau in astrocytes is not through heparan sulfate proteoglycans. Representative western blot (A) and quantification (B) of the
time course of Tau-Cy5 internalization from 0 to 3 h in the presence or absence of heparin. Cells were treated with Tau-Cy5 (control, T) or Tau-Cy5 + heparin (T+Hep)
for different times, and Cy5 was analyzed in cell lysates. Note that the internalization of Tau did not change in the presence of heparin. Means and SE, T
0 h = 0.58 ± 0.06; T+Hep 0 h = 0.71 ± 0.04; T 1 h = 0.96 ± 0.03; T+Hep 1 h = 1.06 ± 0.13; T 3 h = 1.02 ± 0.15; and T+Hep 3 h = 1.09 ± 0.17. Representative
western blot (C) and quantification (D) of Tau-Cy5 with (T+Hase) or without heparinase treatment (T) from 0 to 3 h. Means and SE: T 0 h = 0.23 ± 0.04; T+Hase
0 h = 0.72 ± 0.4; T 1 h = 1.65 ± 0.28; T+Hase 1 h = 1.82 ± 0.17; T 3 h = 1.13 ± 0.03; and T+Hase 3 h = 1.62 ± 0.27. Note that the internalization of Tau did not
change after the treatment with heparinase. Quantification of Tau-Cy5 internalization measured by immunocytochemistry (E) and some representative images of 1 h
time point after treatment (F) confirm the results obtained by western blot. Heparinase treatment reduces HSPGs (G–I). Representative images of CHO cells treated
with 0, 10, or 100 mU/ml of heparinase (G) and quantification of HSPGs (H). Means and SE, control = 10.9 ± 1.02; heparinase 10 mU = 6.9 ± 0.67; and heparinase
100 mU = 2.4 ± 0.29. Quantification of the total area of the cells (I) support that heparinase treatment reduces the presence of HSPGs in the cells. An N = 3
independent experiments were performed. Bars show means ± SE. ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001. Scale bar, 50 µm (F) and 10 µm (G).
the uptake of monomeric Tau species by astrocytes. These results
are in agreement with similar findings obtained in a recent study
performed with α-synuclein (Ihse et al., 2017). Those authors
demonstrated that only aggregated α-synuclein, and not other
species of the protein, was internalized into a range of glial
cells through HSPGs.
It appears that the mechanism by which fibrillary
and/or aggregated Tau enters cells differs from that used
by the monomeric Tau form. In this regard, monomeric
Tau is internalized by muscarinic receptors M1 and M3
(Gomez-Ramos et al., 2006) in neurons; by CX3CR1 receptors
in microglia (Bolos et al., 2017a); and by a non-HSPG-mediated
mechanism in astrocytes. In contrast, the aggregated and
fibrillary form of Tau is taken up by neurons via the
HSPG pathway. These differences could be relevant for the
design of potential drugs that target receptors and have
the capacity to protect against the propagation of Tau in
neurodegenerative diseases.
In summary, here we have shown that extracellular
monomeric Tau is taken up by astrocytes. However, contrary to
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what we expected, this internalization is not HSPG-dependent.
The mechanism by which monomeric Tau enters astrocytes is still
unknown and deserves further attention.
ETHICS STATEMENT
This study was carried out in accordance with European
Community Guidelines (directive 86/609/EEC) and handled
following European and local animal care protocols.
Animal experiments received the approval of the CBMSO’s
Ethics Committee and the National Ethics Committee
(AEEC-CBMSO-62/14).
AUTHOR CONTRIBUTIONS
JD-B, JÁ, FH, and MB conceived and designed the study. JP, EL,
and MB collected the data. JP and MB analyzed the data. MB
wrote the first draft of the manuscript. All the authors read and
approved the final manuscript.
FUNDING
This study was supported by the Spanish Ministry of Economy
and Competitiveness [SAF-2014-53040-P (JÁ) and BFU2016-
77885-P (FH)] and the Centro de Investigación Biomédica
en Red sobre Enfermedades Neurodegenerativas (CIBERNED,
Spain) (JÁ).
ACKNOWLEDGMENTS
The authors would like to thank Esther García and Raquel
Cuadros for their technical assistance and the CBMSO animal
and confocal microscopy facilities for their help with diverse
experimental protocols.
REFERENCES
Arendt, T., Stieler, J. T., and Holzer, M. (2016). Tau and tauopathies. Brain Res. Bull.
126, 238–292. doi: 10.1016/j.brainresbull.2016.08.018
Avila, J., Jimenez, J. S., Sayas, C. L., Bolos, M., Zabala, J. C., Rivas, G., et al. (2016).
Tau Structures. Front. Aging Neurosci. 8:262.
Ballatore, C., Lee, V. M., and Trojanowski, J. Q. (2007). Tau-mediated
neurodegeneration in alzheimer’s disease and related disorders. Nat. Rev.
Neurosci. 8, 663–672. doi: 10.1038/nrn2194
Bolos, M., Llorens-Martin, M., Jurado-Arjona, J., Hernandez, F., Rabano, A., and
Avila, J. (2015). Direct evidence of internalization of tau by microglia in vitro
and in vivo. J. Alzheimers Dis. 50, 77–87. doi: 10.3233/JAD-150704
Bolos, M., Llorens-Martin, M., Perea, J. R., Jurado-Arjona, J., Rabano, A.,
Hernandez, F., et al. (2017a). Absence of CX3CR1 impairs the internalization of
Tau by microglia. Mol. Neurodegener. 12:59. doi: 10.1186/s13024-017-0200-1
Bolos, M., Pallas-Bazarra, N., Terreros-Roncal, J., Perea, J. R., Jurado-Arjona,
J., Avila, J., et al. (2017b). Soluble Tau has devastating effects on the
structural plasticity of hippocampal granule neurons. Transl. Psychiatry 7:1267.
doi: 10.1038/s41398-017-0013-6
Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol. 82, 239–259. doi: 10.1007/bf00308809
Buee, L., and Delacourte, A. (1999). Comparative biochemistry of tau in progressive
supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease.
Brain Pathol. 9, 681–693. doi: 10.1111/j.1750-3639.1999.tb00550.x
Calafate, S., Buist, A., Miskiewicz, K., Vijayan, V., Daneels, G., de Strooper, B., et al.
(2015). Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell
Rep. 11, 1176–1183. doi: 10.1016/j.celrep.2015.04.043
Cowan, C. M., and Mudher, A. (2013). Are tau aggregates toxic or protective in
tauopathies? Front. Neurol. 4:114. doi: 10.3389/fneur.2013.00114
Drubin, D. G., and Kirschner, M. W. (1986). Tau protein function in living cells.
J. Cell Biol. 103, 2739–2746. doi: 10.1083/jcb.103.6.2739
Ferrer, I., Garcia, M. A., Gonzalez, I. L., Lucena, D. D., Villalonga, A. R., Tech,
M. C., et al. (2018). Aging-related tau astrogliopathy (ARTAG): not only tau
phosphorylation in astrocytes. Brain Pathol. 28, 965–985. doi: 10.1111/bpa.
12593
Fox, L. M., William, C. M., Adamowicz, D. H., Pitstick, R., Carlson, G. A., Spires-
Jones, T. L., et al. (2011). Soluble tau species, not neurofibrillary aggregates,
disrupt neural system integration in a tau transgenic model. J. Neuropathol. Exp.
Neurol. 70, 588–595. doi: 10.1097/NEN.0b013e318220a658
Gerson, J. E., Castillo-Carranza, D. L., and Kayed, R. (2014). Advances in
therapeutics for neurodegenerative tauopathies: moving toward the specific
targeting of the most toxic tau species. ACS Chem. Neurosci. 5, 752–769.
doi: 10.1021/cn500143n
Goedert, M., and Spillantini, M. G. (2011). Pathogenesis of the tauopathies. J. Mol.
Neurosci. 45, 425–431. doi: 10.1007/s12031-011-9593-4
Gomez-Ramos, A., Diaz-Hernandez, M., Cuadros, R., Hernandez, F., and Avila, J.
(2006). Extracellular tau is toxic to neuronal cells. FEBS Lett. 580, 4842–4850.
doi: 10.1016/j.febslet.2006.07.078
Gomez-Ramos, A., Diaz-Hernandez, M., Rubio, A., Diaz-Hernandez, J. I., Miras-
Portugal, M. T., and Avila, J. (2009). Characteristics and consequences of
muscarinic receptor activation by tau protein. Eur. Neuropsychopharmacol. 19,
708–717. doi: 10.1016/j.euroneuro.2009.04.006
Holmes, B. B., DeVos, S. L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., et al.
(2013). Heparan sulfate proteoglycans mediate internalization and propagation
of specific proteopathic seeds. Proc. Natl. Acad. Sci. U.S.A. 110, E3138–E3147.
doi: 10.1073/pnas.1301440110
Holmes, B. B., and Diamond, M. I. (2014). Prion-like properties of Tau protein:
the importance of extracellular Tau as a therapeutic target. J. Biol. Chem. 289,
19855–19861. doi: 10.1074/jbc.R114.549295
Hyman, B. T. (2014). Tau propagation, different tau phenotypes, and prion-like
properties of tau. Neuron 82, 1189–1190. doi: 10.1016/j.neuron.2014.06.004
Ihse, E., Yamakado, H., van Wijk, X. M., Lawrence, R., Esko, J. D., and Masliah,
E. (2017). Cellular internalization of alpha-synuclein aggregates by cell surface
heparan sulfate depends on aggregate conformation and cell type. Sci. Rep.
7:9008. doi: 10.1038/s41598-017-08720-5
Katsinelos, T., Zeitler, M., Dimou, E., Karakatsani, A., Muller, H. M., Nachman, E.,
et al. (2018). Unconventional secretion mediates the trans-cellular spreading of
tau. Cell Rep. 23, 2039–2055. doi: 10.1016/j.celrep.2018.04.056
Kovacs, G. G., Ferrer, I., Grinberg, L. T., Alafuzoff, I., Attems, J., Budka, H., et al.
(2016). Aging-related tau astrogliopathy (ARTAG): harmonized evaluation
strategy. Acta Neuropathol. 131, 87–102. doi: 10.1007/s00401-015-1509-x
Leyns, C. E. G., and Holtzman, D. M. (2017). Glial contributions to
neurodegeneration in tauopathies. Mol. Neurodegener. 12:50. doi: 10.1186/
s13024-017-0192-x
Luo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., and Paul, S. M. (2015).
Microglial internalization and degradation of pathological tau is enhanced by
an anti-tau monoclonal antibody. Sci. Rep. 5:11161. doi: 10.1038/srep11161
Maphis, N., Xu, G., Kokiko-Cochran, O. N., Jiang, S., Cardona, A., Ransohoff,
R. M., et al. (2015). Reactive microglia drive tau pathology and contribute
to the spreading of pathological tau in the brain. Brain 138, 1738–1755.
doi: 10.1093/brain/awv081
Martini-Stoica, H., Cole, A. L., Swartzlander, D. B., Chen, F., Wan, Y. W., Bajaj, L.,
et al. (2018). TFEB enhances astroglial uptake of extracellular tau species and
reduces tau spreading. J. Exp. Med. 215, 2355–2377. doi: 10.1084/jem.20172158
Medina, M., and Avila, J. (2014a). Is tau a prion-like protein? J. Alzheimers Dis.
40(Suppl. 1), S1–S3.
Frontiers in Neuroscience | www.frontiersin.org 6 May 2019 | Volume 13 | Article 442
fnins-13-00442 April 29, 2019 Time: 15:11 # 7
Perea et al. Tau Is Internalized by Astrocytes
Medina, M., and Avila, J. (2014b). The role of extracellular Tau in the spreading of
neurofibrillary pathology. Front. Cell Neurosci. 8:113. doi: 10.3389/fncel.2014.
00113
Medina, M., Hernandez, F., and Avila, J. (2016). New features about
tau function and dysfunction. Biomolecules 6:E21. doi: 10.3390/biom602
0021
Medina, M., Montejo de Garcini, E., and Avila, J. (1995). The role of tau
phosphorylation in transfected COS-1 cells. Mol. Cell. Biochem. 148, 79–88.
doi: 10.1007/bf00929506
Odawara, T., Iseki, E., Kosaka, K., Akiyama, H., Ikeda, K., and Yamamoto, T.
(1995). Investigation of tau-2 positive microglia-like cells in the subcortical
nuclei of human neurodegenerative disorders. Neurosci. Lett. 192, 145–148.
doi: 10.1016/0304-3940(95)11595-n
Perea, J. R., Avila, J., and Bolos, M. (2018a). Dephosphorylated rather than
hyperphosphorylated Tau triggers a pro-inflammatory profile in microglia
through the p38 MAPK pathway. Exp. Neurol. 310, 14–21. doi: 10.1016/j.
expneurol.2018.08.007
Perea, J. R., Llorens-Martin, M., Avila, J., and Bolos, M. (2018b). The role of
microglia in the spread of tau: relevance for tauopathies. Front. Cell Neurosci.
12:172. doi: 10.3389/fncel.2018.00172
Perez, M., Cuadros, R., Hernandez, F., and Avila, J. (2016). Secretion of full-
length tau or tau fragments in a cell culture model. Neurosci. Lett. 634, 63–69.
doi: 10.1016/j.neulet.2016.09.026
Pooler, A. M., Phillips, E. C., Lau, D. H., Noble, W., and Hanger, D. P. (2013).
Physiological release of endogenous tau is stimulated by neuronal activity.
EMBO Rep. 14, 389–394. doi: 10.1038/embor.2013.15
Rauch, J. N., Chen, J. J., Sorum, A. W., Miller, G. M., Sharf, T., See, S. K., et al.
(2018). Tau internalization is regulated by 6-o sulfation on heparan sulfate
proteoglycans (HSPGs). Sci. Rep. 8:6382. doi: 10.1038/s41598-018-24904-z
Selkoe, D. J., Ihara, Y., and Salazar, F. J. (1982). Alzheimer’s disease: insolubility of
partially purified paired helical filaments in sodium dodecyl sulfate and urea.
Science 215, 1243–1245. doi: 10.1126/science.6120571
Simon, D., Garcia-Garcia, E., Royo, F., Falcon-Perez, J. M., and Avila, J. (2012).
Proteostasis of tau. Tau overexpression results in its secretion via membrane
vesicles. FEBS Lett. 586, 47–54. doi: 10.1016/j.febslet.2011.11.022
Spires-Jones, T. L., Stoothoff, W. H., de Calignon, A., Jones, P. B., and Hyman,
B. T. (2009). Tau pathophysiology in neurodegeneration: a tangled issue. Trends
Neurosci. 32, 150–159. doi: 10.1016/j.tins.2008.11.007
Stopschinski, B. E., Holmes, B. B., Miller, G. M., Manon, V. A., Vaquer-Alicea,
J., Prueitt, W. L., et al. (2018). Specific glycosaminoglycan chain length and
sulfation patterns are required for cell uptake of tau versus alpha-synuclein
and beta-amyloid aggregates. J. Biol. Chem. 293, 10826–10840. doi: 10.1074/jbc.
RA117.000378
Wang, Y., Balaji, V., Kaniyappan, S., Kruger, L., Irsen, S., Tepper, K., et al.
(2017). The release and trans-synaptic transmission of Tau via exosomes. Mol.
Neurodegener. 12:5. doi: 10.1186/s13024-016-0143-y
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., and Kirschner, M. W. (1975). A
protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. U.S.A.
72, 1858–1862. doi: 10.1073/pnas.72.5.1858
Yamada, M., and Hamaguchi, T. (2018). The sulfation code for propagation of
neurodegeneration. J. Biol. Chem. 293, 10841–10842. doi: 10.1074/jbc.H118.
003970
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Perea, López, Díez-Ballesteros, Ávila, Hernández and Bolós. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 7 May 2019 | Volume 13 | Article 442
